Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METIMMOX in microsatellite-stable metastatic colorectal cancer
2017-001845-29Phase 2Completed
- Sponsor
- Akershus University Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and oxaliplatin in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Akershus University Hospital. Primary endpoint: Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
nivolumaboxaliplatin
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-001845-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001845-29.